Williams, Astrid-Jane http://orcid.org/0000-0002-1756-5329
Karimi, Neda
Chari, Radha
Connor, Susan
De Vera, Mary A.
Dieleman, Levinus A.
Hansen, Tawnya
Ismond, Kathleen
Khurana, Rshmi
Kingston, Dawn
O’Connor, Katie
Sadowski, Daniel C.
Fang-Hwa, Flora
Wine, Eytan
Leung, Yvette
Huang, Vivian
Funding for this research was provided by:
Women and Children's Health Research Institute (Clinical/Community Research Integration Support Program)
Merck Better Care (Healthy Communities Funding Program)
Gastroenterological Society of Australia (Rose Amarant Grant to)
Article History
Received: 6 December 2020
Accepted: 21 June 2021
First Online: 30 July 2021
Declarations
:
: The study had ethics approval from the associated institutions: UNSW (Human Research Ethics Committee number: 2019/ETH00254); UBC (Research Ethics Board Number: H17-02354); U of T (Research Ethics Board Number: 18-0215-E); U of A (Pro00071492 Decision Making for Women with IBD). Informed written consent was obtained from participants involved in the study.
: Not applicable.
: AJW: Honoraria received from Takeda, Janssen, Pfizer and Abbvie and Honoraria and grant support from Ferring. NK: Grant support received from Janssen and educational support from Ferring. RC, KPI, RK, DK, KO, DCS, FFT: No COI. SJC: Honoraria for Advisory Board participation, speaker fees, educational support and/or research support from Abbvie, BMS, Celltrion, Chiesi, DrFalk, Ferring, Fresenius Kabi, Gilead, Janssen, MSD, Novartis, Pfizer, Takeda. MADV: Canada Research Chair in Medication Adherence, Utilization, and Outcomes. LAD: Honoraria received from Janssen, Abbvie and Pfizer. TH: Advisory boards of Takeda Canada and Johnson Canada and research funding from Pfizer Canada. EW: Honoraria received from Abbvie, Janssen, Nestle. YPL: Honoraria for Advisory Board participation and speaker fees from Janssen, Abbvie, Takeda, Pfizer and Merck. VWH: Honoraria received from Abbvie, Ferring, Janssen, Merck, Pfizer, Roche, Takeda.